ArticleAmerican heart journal2014
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012.
Article in American heart journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02273609 (English), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
English: Current Perspective of the Status of Anticoagulation in Clinical Practice in Primare Care. Spanish: Perspectiva Actual de la sitUación de la anticoaguLación en la práctica clínica de Atención Primaria.
Who cites it
24 citing papers in PubMed, 55 citations in OpenAlex.
- Article
- Personalized Antithrombotic Strategies in Patients with Atrial Fibrillation Following Transcatheter Aortic Valve Replacement.Journal of personalized medicine · 2025Article
- Oral anticoagulation use in non-valvular atrial fibrillation patients in rural setting.American journal of medicine open · 2023Article
- Anticoagulation under-utilization in atrial fibrillation patients is responsible for a large proportion of strokes requiring endovascular therapy.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2023Article
- The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community.BMC primary care · 2023Article
- Knowledge, attitude and practice toward oral anticoagulants among patients with atrial fibrillation.Frontiers in cardiovascular medicine · 2023Article
- Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans.Journal of managed care & specialty pharmacy · 2022Article
- Primary care provider payment models and adherence to anticoagulation in patients with atrial fibrillation.Journal of managed care & specialty pharmacy · 2021Article
- Variation in Antithrombotic Therapy and Clinical Outcomes in Patients With Preexisting Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement: Insights From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry.Circulation. Cardiovascular interventions · 2021Article
- Article
- Engaging Patients in Atrial Fibrillation Management via Digital Health Technology: The Impact of Tailored Messaging.The Journal of innovations in cardiac rhythm management · 2020Article
- Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2020Article
- Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation.Journal of the American Heart Association · 2019Article
- Thromboprophylaxis for Patients with High-risk Atrial Fibrillation and Flutter Discharged from the Emergency Department.The western journal of emergency medicine · 2018Article
- Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.Pharmacoepidemiology and drug safety · 2017Article
- Thromboembolism and bleeding risk scores and predictors of cardiac death in a population with atrial fibrillation.Arquivos brasileiros de cardiologia · 2017Observational
- Antithrombotic prophylaxis of atrial fibrillation in an Italian real-world setting: a retrospective study.Vascular health and risk management · 2017Observational
- Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal.Critical care (London, England) · 2016Review
- Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands.International journal of clinical pharmacy · 2015Observational
- Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 13 institutions in 4 countries.
Funding
Abstract
Approximately half of patients with atrial fibrillation and with risk factors for stroke are not treated with oral anticoagulation (OAC), whether it be with vitamin K antagonists (VKAs) or novel OACs (NOACs); and of those treated, many discontinue treatment. Leaders from academia, government, industry, and professional societies convened in Washington, DC, on December 3-4, 2012, to identify barriers to optimal OAC use and adherence and to generate potential solutions. Participants identified a broad range of barriers, including knowledge gaps about stroke risk and the relative risks and benefits of anticoagulant therapies; lack of awareness regarding the potential use of NOAC agents for VKA-unsuitable patients; lack of recognition of expanded eligibility for OAC; lack of availability of reversal agents and the difficulty of anticoagulant effect monitoring for the NOACs; concerns with the bleeding risk of anticoagulant therapy, especially with the NOACs and particularly in the setting of dual antiplatelet therapy; suboptimal time in therapeutic range for VKA; and costs and insurance coverage. Proposed solutions were to define reasons for oral anticoagulant underuse classified in ways that can guide intervention and improve use, to increase awareness of stroke risk as well as the benefits and risks of OAC use via educational initiatives and feedback mechanisms, to better define the role of VKA in the current therapeutic era including eligibility and ineligibility for different anticoagulant therapies, to identify NOAC reversal agents and monitoring strategies and make knowledge regarding their use publicly available, to minimize the duration of dual antiplatelet therapy and concomitant OAC where possible, to improve time in therapeutic range for VKA, to leverage observational data sets to refine understanding of OAC use and outcomes in general practice, and to better align health system incentives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.